Overview

Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the activity of nerispirdine in improving the ability to walk, in patients with multiple sclerosis (MS). Secondary objectives: - To assess other measures of walking ability, tiredness, and lower limb muscular strength, spasticity, clinical assessment by subject and clinical assessment of change by the Study Investigator - To assess the safety and tolerance of nerispirdine - To evaluate the pharmacokinetics (PK) parameters of nerispirdine
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi